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Background: Neurotrophic factors such as brain derived neurotrophic factor (BDNF) are synthesized in a variety of
neural and non-neuronal cell types and regulate survival, proliferation and apoptosis. In addition, bone
morphogenetic proteins (BMPs) inhibit the proliferation of pulmonary large carcinoma cells bone morphogenetic
protein receptor, type IA (BMPR1A). Little is known about the expression of BDNF or BMPR1A in malignant gall
bladder lesions. This study was to evaluate BDNF and BMPR1A expression and evaluate the clinicopathological
significance in benign and malignant lesions of the gallbladder.
Methods: The BDNF and BMPR1A expression of gallbladder adenocarcinoma, peritumoral tissues, adenoma, polyp
and chronic cholecystitis were Immunohistochemically determined.
Results: BDNF expression was significantly higher in gallbladder adenocarcinoma than in peritumoral tissues,
adenoma, polyps and chronic cholecystitis samples. However, BMPR1A expression was significantly lower in
gallbladder adenocarcinoma than in peritumoral tissues, adenomas, polyps and chronic cholecystitis tissues. The
specimens with increased expression of BDNF in the benign lesions exhibited moderate- or severe-dysplasia of
gallbladder epithelium. BDNF expression was significantly lower in well-differentiated adenocarcinomas with
maximum tumor diameter <2 cm, no metastasis to lymph nodes, and no invasion of regional tissues compared to
poorly-differentiated adenocarcinomas with maximal tumor diameter >2 cm, metastasis of lymph node, and
invasiveness of regional tissues in gallbladder adenocarcinoma. BMPR1A expression were significantly higher in the
well-differentiated adenocarcinoma with maximal tumor diameter <2 cm, no metastasis of lymph node, and no
invasion of regional tissues compared to poorly-differentiated adenocarcinomas with maximal tumor diameter >2 cm,
metastasis of lymph node, and invasiveness of regional tissues in gallbladder. Univariate Kaplan-Meier analysis indicated
increased expression of BDNF or decreased expression of BMPR1A was associated with decreased disease specific
survival (DSS) rates. Similarly, multivariate Cox regression analysis showed increased expression of BDNF or decreased
expression of BMPR1A are independent predictors of poor DSS rates in gallbladder adenocarcinoma.
Conclusions: In gallbladder malignancies, the increased expression of BDNF and decreased expression of BMPR1A
were associated with increased risk of metastasis, regional invasion and mortality. They might serve as novel indicators
of gallbladder adenocarcinoma outcomes, which may prove valuable for the development of personalized therapeutic
paradigms.
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Gallbladder cancer is the most common biliary tract
malignancy and the fifth most common malignant
neoplasm of the digestive tract [1]. Despite recent advances
in the diagnosis and management of gastrointestinal
cancers, cancer of the gallbladder remains a neoplasm
with a high mortality rate and poor overall prognosis.
More than 85% of gallbladder cancers are adenocarcinomas
that are well or moderately differentiated, while the
remaining 15% are squamous, adenosquamous, or
undifferentiated carcinoma [2]. Many of these tumors are
not resectable at the time of presentation because of local
invasion of crucial gallbladder structures, or metastasis
into surrounding tissues and lymph nodes. The primary
TMN (tumor, node, meta stasis’ age is a significant
prognostic factor, and the 5-year survival rate for patients
with T3 or T4 carcinoma has been reported as less
than 15% [3]. Therefore, better understanding of the
pathogenesis of gallbladder cancer, including the expression
of tumor-specific markers, should provide a basis for
developing novel therapies [4].
Brain-derived neurotrophic factor (BDNF), a secreted
protein, is a member of the neurotrophin growth factor
family. BDNF is expressed by several human tumors,
and is a key regulator of oncogenesis, tumor invasion, and
tumor progression. BDNF knockdown may inhibit tumor
invasion of HepG2 and HCCLM3 cells [5,6]. Recent studies
have shown that high expression levels of BDNF have a
significant relationship with the tumorigenesis, progression,Figure 1 Expression of brain-derived neurotrophic factor (BDNF) and
benign and malignant gallbladder lesions. (A) Positive expression of BD
benign lesion. (C) Negative expression of BMPR1A in adenocarcinoma and
reaction for both BDNF and BMPR1A was mainly localized to the cytoplasmbiological behavior, and prognosis of breast cancers [7,8].
Furthermore, Artico et al. recently reported that increased
expression of BDNF was clearly visible in gallbladder
carcinoma, suggesting a direct role of this neurotrophic
factor in the transformation and progression of neoplastic
cells of gallbladder tissue. However, whether increased
expression of BDNF is associated with disease prognosis
remains unknown.
Bone morphogenetic proteins (BMPs) are a group of
multifunctional growth factors of the transforming growth
factor (TGF)-β superfamily of cytokines [9,10]. Numerous
studies have shown that these morphogens play crucial
roles during development and in the regulation of cell
proliferation, differentiation, and apoptosis [11]. BMPs
exert their biological effects through bone morphogenetic
protein receptor type 1A (BMPR1A), also known as
ALK3, which is a transmembrane serine/threonine kinase
expressed in several tissues and cancers [12]. BMPR1A is
a type I receptor of the TGF-β superfamily, with a
cysteine-rich extracellular region, an intracellular glycine–
serine-rich (GS) domain near the plasma membrane, and
an intracellular kinase domainBMPR1A mediates BMP
intracellular signaling, which is associated with carcino-
genesis, through MADH4 [13,14]. Recent studies have
reported that low BMPR1A expression in tumors may be
associated with poor prognosis [15,16]. However, the
expression levels of BDNF and BMPR1A and their clinico-
pathologic significance in malignant tumors, particularly
gallbladder cancer, have not been thoroughly evaluated.bone morphogenetic protein receptor type IA (BMPR1A)in
NF in adenocarcinoma, and (B) negative expression of BDNF in a
(D) positive expression of BMPR1A in a benign lesion. The positive
and/or cell membrane. Original magnification × 200.
Table 1 Expression of brain-derived neurotrophic factor (BDNF) and bone morphogenetic protein receptor type IA
(BMPR1A) in gallbladder adenocarcinoma, peritumoral, adenoma, polyp, and chronic cholecystitis tissues
Tissue Total, n BDNF BMPR1A
Positive, n (%) χ2 P Positive, n (%) χ2 P
Gallbladder adenocarcinoma 100 55 (55.0) 53 (53.0)
Peritumoral tissues 46 12 (26.1) 10.61 <0.01 36 (78.3) 8.45 <0.01
Adenoma 30 7 (23.3) 9.28 <0.01 24 (80.0) 6.97 <0.01
Polyp 15 2 (13.3) 9.06 <0.01 12 (80.0) 3.87 <0.01
Chronic cholecystitis 35 4 (11.4) 20.01 <0.01 31 (88.6) 13.96 <0.01
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Ethics approval
This study was approved by the institutional ethics
committee of Second Xiangya Hospital, Central South
University, and performed in accordance with the
Declaration of Helsinki (2000) of the World Medical
Association. All patients provided written informed
consent.
Specimens and clinicopathologic material
Surgically resected or biopsy specimens were collected
from Xiangya Hospital (Central South University,
Hunan, PR China), between 1996 and 2011. Adenoma
specimens were collected from 100 patients with
gallbladder adenocarcinoma (70 women, 30 men; meanFigure 2 Expression of brain-derived neurotrophic factor (BDNF) and
gallbladder adenocarcinoma, peritumoral, adenoma, polyp, and chroage 52.4 ± 11.3 years). In addition, 46 peritumoral tissues
were harvested from these 100 adenocarcinomas, and we
also obtained 15 gallbladder polyp tissues, 30 gallbladder
adenoma tissues, and 35 chronic cholecystitis tissues from
other patients. All diagnoses were based on morphological
criteria, immunohistochemical staining, and clinical
findings. The histopathological subtypes of the 100
adenocarcinoma specimens were: 36 well-differentiated
adenocarcinomas, 29 moderately differentiated adenocar-
cinomas, 25 poorly differentiated adenocarcinomas, and
10 mucinous adenocarcinomas. Of the 100 patients with
adenocarcinoma, 54 had invasion of surrounding tissues
and organs, 59 had regional lymph-node metastasis, and
58 had gallstones. According to the standard criteria for T
stages [17], of the 100 adenocarcinomas, 22 were at stagebone morphogenetic protein receptor, type IA (BMPR1A) in
nic cholecystitis tissues.
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were performed in 32 of the adenocarcinoma patients,
palliative surgery in 46, and biopsy in the remaining
22 patients. Follow-up was completed for 65 of the
100 patients by letters and phone calls; these data showed
that 20 patients survived over 1 year, and 45 patients
survived for less than 1 year.
Of the 46 peritumoral tissues (distance from cancer ≥
3 mm), 10 were classified as normal, while 10 had
mild dysplasia, 12 had moderate dysplasia, and 14
had severe dysplasia. The diameters of the 15 gallbladder
polyps ranged from 8 to 15 mm. Ten of the cases were
pathologically classified as having normal epithelium to
mild dysplasia, and five cases as having moderate to severe
dysplasia. The diameter of the 30 gallbladder adenomasTable 2 Expression of brain-derived neurotrophic factor (BDN
(BMPR1A) and their correlation with the clinicopathologic pa
Clinicopathologic features Cases BDNF
Positive cases, n (%)
Gender
Male 30 13 (43.3)
Female 70 42 (60.0)
Age, years
≤ 45 22 10 (45.5)
> 45 78 45 (57.7)
Pathological typea,b,c
Well differentiated 36 13 (36.1)
Moderately differentiated 29 16 (55.2)
Poorly differentiated 25 20 (80.0)
Mucinous adenocarcinoma 10 6 (60.0)
Maximum diameter of mass, mm
< 20 29 11 (37.9)
≥ 20 71 44 (62.0)
Metastasis to lymph node
No 47 19 (40.4)
Yes 53 36 (67.9)
Invasion to surrounding tissue
No 46 20 (43.5)
Yes 54 35 (64.8)
T stage
T1 22 8 (36.4)
T2 35 16 (45.7)
T3 29 21 (72.4)
T4 14 10 (71.4)
Gallstones
No 47 23 (48.9)
Yes 53 32 (60.4)
aWell-differentiated compared with moderately differentiated for BDNF: χ = 2.36, P >
bWell-differentiated compared with poorly differentiated for BDNF: χ2 = 11.44, P < 0.
cModerately differentiated compared with poorly differentiated for BDNF: χ2 = 3.72,was between 9 to 22 mm. There were five cases
pathologically confirmed as normal mucosa, ten as mild
dysplasia, nine as moderate dysplasia, and six as severe
dysplasia. Of the 35 patients with chronic cholecystitis,
15 had chronic cholecystitis alone, whereas the other
20 patients had chronic cholecystitis accompanied by
gallstones. The pathological examination confirmed
that 11 of the gallbladders had normal mucosa, 12
had mild dysplasia, 7 had moderate dysplasia, and 5 had
severe dysplasia.
Immunohistochemistry
Sections 4 μm thick were cut from routinely processed
tissues that had been embedded in paraffin wax.
Immunohistochemical staining was carried out usingF) and bone morphogenetic protein receptor type IA
rameters of gallbladder adenocarcinoma
BMPR1A
χ2 P Positive cases, n (%) χ2 P
2.36 >0.05 14 (46.7) 0.69 >0.05
39 (55.7)
1.04 >0.05 10 (45.5) 0.65 >0.05
43 (55.1)




4.81 <0.05 20 (69.0) 4.18 <0.05
33 (46.5)
7.61 <0.01 31 (66.0) 5.98 <0.05
22 (41.5)
4.57 <0.05 30 (65.2) 5.10 <0.05
23 (42.6)




1.32 >0.05 22 (46.8) 1.37 >0.05
31 (58.5)
0.05; and for BMPR1A: χ2 = 1.56, P > 0.05.
01; and for BMPR1A: χ2 = 9.68, P < 0.01.
P = 0.05; and for BMPR1A: χ2 = 1.47, P > 0.05.
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antibodies (gift from Abgent Company, San Diego
CA, USA) and a commercial kit (EnVisionTM Detection
Kit; Dako Laboratories, Carpinteria, CA, USA) in accord-
ance with the manufacturer’s protocol (ChemMateTM
EnVision+/HRP/DAB).
Briefly, the sections were dewaxed in distilled water,
and incubated with peroxidase inhibitor (3% H2O2) in
the dark for 15 minutes, then washed with distilled
water, followed by EDTA-trypsin digestion (0.125%,
pH 9.0) for 15 minutes, and further washing with
distilled water. After incubating the sections three times
in phosphate-buffered saline (PBS, pH 7.4) for 5 minutes
each the sections were removed and the liquid around the
tissues removed, without drying the tissues themselves.
The sections were then incubated with rabbit anti-BDNF
or anti-BMPR1A for 60 minutes at room temperature.
The sections were socked in PBS three times for 5 minutes
each, then the sections were removed, and the liquid
wiped from around the tissues as before. The first solution
from the kit (solution A) was added to the sections, which
were incubated for 30 minutes at room temperature,
then the sections were removed, and the liquid wipedFigure 3 Expression of brain-derived neurotrophic factor (BDNF) and
their correlation with the clinicopathologic parameters of gallbladderfrom around the tissues as before. Diaminobenzidine
substrate was added to the sections and left for of 5 to
10 minutes at room temperature. After staining was
complete, the sections were washed with distilled water,
then counterstained with hematoxylin for 1 minute, and
incubated in distilled water for 15 minutes. The slides
were dehydrated with increasing concentrations (70 to
100%) of alcohol, each for 3 minutes. The sections were
incubated in xylene three times for 5 minutes, and finally
mounted on slides with neutral balsam.
Cells in the cytoplasm and cell membrane containing
brown-yellow granules were defined as positive cells.
The percentage of positive BDNF or BMPR1A cells was
calculated from 10 random high fields. The sample was
considered positive when the percentage of stained cells
was 25% or higher, and considered negative when the
percentage of stained was less than 25%.
Statistical analysis
The data were analyzed using SPSS software (version 13.0;
SPSS Inc., Chicago, IL, USA). The inter-relationship of
BDNF or BMPR1A expression with the histological or
clinical factors was analyzed by the independent χ2 test.bone morphogenetic protein receptor type IA (BMPR1A) and
adenocarcinoma.
Table 3 Relationships between brain-derived
neurotrophic factor (BDNF) and bone morphogenetic
protein receptor type IA (BMPR1A) expression and
clinicopathologic characteristics and average survival of
patients with gallbladder adenocarcinoma
Clinicopathologic
characteristics




Male 18 10.0 (4 to 16) 0.910
Female 47 10.0 (4 to 18)
Age, years
≤ 45 11 8.0 (4 to 14) 0.121
> 45 54 10.0 (4 to 18)
Pathological type
Well differentiated 27 11.2 (4 to 18) 0.03
Moderately differentiated 20 10.0 (4 to 18)
Poorly differentiated 12 8.0 (4 to 10)
Mucinous adenocarcinoma 6 10.0 (6 to 16)
Maximum, diameter of mass, mm
< 20 19 14.0 (4 to 18) 0.003
≥ 20 46 8.0 (4 to 18)
Metastasis to lymph node
No 35 12.0 (4 to 18) 0.005
Yes 30 8.0 (4 to 18)
Invasion to surrounding tissue
No 38 10.0 (4 to 18) 0.002
Yes 27 8.0 (4 to 16)
T stage
T1 14 12.6 (6 to 18) 0.031
T2 23 10.7 (4 to 18)
T3 19 8.0 (4 to 18)
T4 9 6.2 (4 to 10)
Gallstones
No 29 10.9 (4 to 18) 0.135
Yes 36 9.8 (4 to 18)
BDNF
Positive 32 9.1 (4 to 18) 0.013
Negative 33 11.9 (6 to 18)
BMPR1A
Positive 31 11.7 (6 to 18) 0.042
Negative 34 9.5 (4 to 18)
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statistical association between the two independent
sample groups. Kaplan–Meier and log-rank tests were
used for univariate survival analysis. The Cox proportional
hazards model was used for multivariate analysis and to
determine the 95% confidence interval.
Results
Expression levels of brain-derived neurotrophic factor
and bone morphogenetic protein receptor type IA in
benign and malignant gallbladder lesions
Positive immunohistochemical staining for BDNF and
BMPR1A was seen in the cytoplasm and/or on the cell
membrane (Figure 1A–D). BDNF was significantly higher
(positive) and BMPR1A was significantly lower (negative)
in gallbladder adenocarcinoma than in peritumoral tis-
sues, adenoma, polyps, and chronic cholecystitis (P < 0.01
for both) (Table 1, Figure 2). In addition, the BDNF
positivity and BMPR1A negativity in peritumoral
tissues, polyps, and chronic cholecystitis epithelium was
accompanied by moderate or severe dysplasia. When
all100 gallbladder adenocarcinoma, 46 peritumoral, 30
adenoma, 15 polyp and 35 chronic cholecystitis samples
were assessed, the positive rate of BDNF was inversely
related to that of BMPR1A, due to the analysis of Pearson
correlation coefficients (r = −7.482, P < 0.05).
Expression of brain-derived neurotrophic factor and bone
morphogenetic protein receptor type IA and evaluation
of correlation with the clinicopathologic features of
gallbladder adenocarcinoma
BDNF expression was significantly lower (P < 0.05) and
BMPR1A was significantly higher (P < 0.05) in the
well-differentiated gallbladder adenocarcinomas with
maximum diameter of <20 mm, no metastasis to
lymph nodes, and no invasion of regional tissues,
compared with poorly differentiated tissues with maximal
mass diameter of >20 mm, metastasis to lymph nodes,
and invasion of regional tissues. There was no correlation
between expression of BDNF or BMPR1A and age, gender,
or presence or absence of gallstones (P > 0.05) (Table 2,
Figure 3).
Correlation of brain-derived neurotrophic factor and bone
morphogenetic protein receptor type IA expression with
disease-specific survival of gallbladder adenocarcinoma
Follow-up at year5 was carried out by phone or mail
surveys, and data were collected from 65of the 100
patients. Of these 65 patients, 20 had a survival of
over 1 year, and the remaining 45 died within 1 year
after surgery as a result of tumor progression, with a
mean survival time of 9.7 ± 5.4 months. Positive
immunohistochemical staining for BDNF was foundfor 32 (49.2%) of the 65 patients, and positive staining for
BMPR1A was found for 31 (47.7%) of the 65 patients.
The relevance of positive BDNF and BMPR1A expres-
sion to patient survival was examined by univariate
Kaplan–Meier survival analysis. The relevance of
disease-specific survival (DSS) to the clinicopathologic
characteristics was as follows.DSS was positively associated
with tumor pathological type (P = 0.030), tumor
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invasion of surrounding tissues (P = 0.002), and T stage
(P = 0.031). DSS was inversely associated with positive
expression of BDNF (P = 0.013) (Table 3, Figure 4), but
positively correlated with positive expression of
BMPR1A (P = 0.042) (Table 3, Figure 4). MultivariateFigure 4 Relationship between brain-derived neurotrophic factor and
survival in patients with gallbladder adenocarcinoma. (A,B) Kaplan–Me
adenocarcinomaand (A) BDNF-positive and BDNF-negative expression or (BCox regression survival analysis indicated that tumor
maximum diameter of 20 mm or more, lymph-node
metastasis, and invasion to surrounding tissue, followed
by BDNF-positive expression or BMPR1A-negative
expression were the most significant predictors of short
DSS (Table 4).bone morphogenetic protein receptor type IA expression and
ier plots of the disease-specific survival of patients with gallbladder
) BMPR1A-positive and BMPR1A-negative expression.
Table 4 Multivariate Cox regression analysis of disease-specific survival in 65 patients who underwent surgical
resection of gallbladder carcinoma
Group Category B SE (B) Exp (B) P 95% CI for Exp (B)
Inferior Superior
Pathology type Well/moderately/poorly differentiated
carcinoma/mucous carcinoma
0.621 0.359 1.861 0.084 0.92 3.76
Tumor diameter <20/20 mm 1.127 0.411 3.086 0.006 1.38 6.91
Lymph-node metastasis No/yes 1.421 0.482 4.141 0.003 1.61 10.65
Invasion to surrounding tissue No/yes 1.120 0.385 3.065 0.004 1.44 6.52
Surgery Radical/ palliative 1.340 0.457 3.819 0.003 1.66 9.35
BDNF Positive/negative 1.406 0.439 4.080 0.001 1.73 9.65
BMPR1A Negative/positive −0.885 0.389 0.413 0.023 0.19 0.89
Abbreviations: BDNF, brain-derived neurotrophic factor; BMPR1A bone morphogenetic protein receptor type IA; Exp, exponential; SE, standard error. B in SPSS
means regression coefficient. SE (B) means Standard error B. Exp(B) in SPSS means Hazard ratio, also called relative risk.
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In the current study, we found that increased expression
of BDNF or decreased expression of BMPR1A were
independent predictors of poor DSS rates in gallbladder
adenocarcinoma. These findings suggest that these two
factors might provide a novel evaluation method for deter-
mining the outcomes of various gallbladder tumor types.
Previous studies have shown high levels of BDNF and
its receptor tropomyosin-related kinase B (TrkB) in various
cancer types, including carcinomas of the ovary [18], colon,
rectum [19], liver [20], mammary [21], cervix [5], bladder
[21], chorion [22] and prostate [23]. However, the precise
role of BDNF in the pathogenesis of cancer has not been
fully explored. BDNF expression was reported to be
significantly associated with tumor-progression factors
such as poor differentiation, advanced tumor stage, and
lymph-node invasion [24,25]. BDNF expression directly
enhances the proliferation, survival, migratory capability,
and invasiveness of tumor cells. Studies on head and neck
squamous cell carcinoma (HNSCC) cell lines showed that
in vitro stimulation with BDNF upregulated the migration
and invasion of HNSCC cells, and both transient
and stable suppression of TrkB resulted in significant
abrogation of both constitutive and ligand-mediated
migration and invasion. Using an in vivo mouse
model of HNSCC, it was shown that downregulation
of TrkB suppresses tumor growth. In human breast
cancer, there was substantially greater BDNF expression
within neoplastic cells compared with normal mammary
epithelial cells. Similar to the current study, higher BDNF
expression was significantly associated with nodal positivity,
local recurrence, death from cancer, and poor overall
prognosis [7]. These data suggest that BDNF may have a
crucial function in mediating tumor relapse, metastasis,
anti-apoptosis, and chemotherapeutic resistance in the
various diseases mentioned above, and the involvement of
BDNF in key cancer-related pathways makes it an attractive
target for molecular targeted therapy [26,27].BMPs are multifunctional signaling molecules that
belong to the TGF-β superfamily. They were first
identified based on their ability to form bone at extra
skeletal sites. Later, it became evident that these
bone-inducing factors also play crucial roles during
development, regulating cell proliferation, differentiation,
and apoptosis [27]. BMPs signal by binding to two
separate (type I and II) transmembrane serine/threonine
kinase receptors [28]. Three type I and type II receptors
specifically bind BMP ligands. Type I receptors consist of
BMPR1A (also known as ALK-3), BMPR1B (ALK-6), and
activin A receptor type I (ACVR1; also known as ALK-2).
However, the signaling mechanisms activated by these
three receptor subtypes are not well known. We
speculate that the various effects of BMPs on proliferation,
differentiation, and apoptosis of tumor cells may be
related to the expression levels of BMPR1A. Several
studies have shown that BMPR1A plays a role in sup-
pression of tumor progression [29,30]. In the current
study, we found that BMPR1A levels were lower in
gallbladder adenocarcinoma compared with benign
samples. Similar to these findings, a previous study
reported that benign prostate specimens expressed high
levels of BMPR1A; however, prostate-cancer specimens
expressed much lower levels of BMPR1A, which suggests
that loss of BMPR1A may play a vital role during the
progression of prostate cancer [15]. The conditions
juvenile polyposis syndrome (JPS) and hereditary mixed
polyposis syndrome (HMPS) are associated with an
increased risk of colorectal carcinoma. Mutations in the
BMPR1A gene have been identified in up to 20% of patients
with JPS [31,32], and HMPS has also been associated with
mutations in the BMPR1A gene [33]. BMPR1A has also
been reported to be a tumor suppressor in skin tumorigen-
esis [16]. However, it should be noted that contradictory
findings were found for squamous cell carcinoma of the
lower lip, where strong expression of BMPR1A showed a
significant association with advanced clinical staging and
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that decreased expression of BMPR1A contributes to
metastasis and poor prognosis in gallbladder cancer.
Therefore, we found in the current study that positivity
rates of were significantly higher for BDNF and signifi-
cantly lower for BMPR1A in gallbladder adenocarcinoma
compared with peritumoral adenomatous polyp, and
chronic cholecystitis tissues. These findings indicate that
BDNF and BMPR1A may be independent tumor markers
reflecting the genesis, progression, biological behavior, and
prognosis of gallbladder adenocarcinoma. More extensive
studies are required to determine the mechanistic roles of
BDNF and BMPR1A in the development and progression
of gallbladder cancer.
Ortega et al. showed that BDNF induced expression
of BMP7in embryonic neurons, induced the early
differentiation of radial glia into glial precursors and
astrocytes, and impaired neuronal migration [35]. Xu
et al. showed that BMP7 signaling via BMPR1A and
BMPR1B inhibited the proliferation of pulmonary
large carcinoma cell NCI-H460 [36]. We suggest that
there may be a relationship between BDNF and BMPR1A,
but it remains unclear how BDNF and BMPR1A together
affect the action of tumors, such as gallbladder cancer.
BDNF and its receptor TrkB have recently emerged as
anticancer targets. De Farias et al. found increased BDNF
levels in colorectal cancer tumor samples [37]. The
inhibitory effect of cetuximab on cell proliferation and
survival was counteracted by the addition of human
recombinant BDNF. Thus, it is possible that targeting trkB
could potentiate the anticancer effects of cetuximab
therapy [37]. Bleuming et al. reported that BMP signaling
via BMPR1A suppresses tumorigenesis at gastric epithelial
transition zones [29]. We suggest that the findings
from the current study could also be used to develop
personalized therapeutic methods for gallbladder cancer
based on our findings.
Conclusion
In the current study, increased expression of BDNF and
decreased expression of BMPR1A were associated with
increased risk of metastasis, regional invasion, and mortality
in gall bladder carcinoma. These markers might be useful
as novel indicators of gallbladder adenocarcinoma outcome,
assisting in the development of personalized therapies.
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